Clinical trial
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With…
NCT00025532 · University of California, San Francisco, Other · Withdrawn
Key facts
| NCT number | NCT00025532 |
|---|---|
| Title | Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer |
| Official title | A Pre-Phase I Biodistribution Study Of hCC^CH2 Labeled With 131 Iodine In Patients With Gastrointestinal Adenocarcinomas |
| Lead sponsor | University of California, San Francisco, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer |
| Intervention type | Other |
| Interventions | iodine I 131 monoclonal antibody CC49-deltaCH2 |
| Enrollment | 0 |
| Start date | Apr 1, 2001 |
| First posted | Nov 21, 2003 |
| Last update posted | Sep 14, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: